Evogene Q2 EPS $(0.17), Inline, Sales $654.00K Miss $880.00K Estimate
Portfolio Pulse from Benzinga Newsdesk
Evogene reported Q2 losses of $(0.17) per share, in line with analyst consensus. This is a 19.05% increase over losses from the same period last year. However, the company's quarterly sales of $654.00K missed the analyst consensus estimate of $880.00K by 25.68%, despite being a 109.62% increase over sales from the same period last year.
August 17, 2023 | 11:03 am
News sentiment analysis
Sort by:
Descending
NEGATIVE IMPACT
Evogene's Q2 earnings were in line with estimates, but sales missed expectations by 25.68%. This could potentially impact the company's stock negatively in the short term.
While Evogene's Q2 earnings per share were in line with analyst expectations, the company's sales fell short of estimates by 25.68%. This could lead to a negative sentiment among investors, potentially causing a short-term decrease in the company's stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100